News

Open For Business Dana Cipriano, Global Head of Analytical Services, cuts the ribbon to mark the opening of SK pharmteco’s state-of-the-art 20,000-square-foot CGMP testing facility at SK pharmteco’s King of Prussia campus. The facility is the future home of SK pharmteco’s Lentiviral Vector (LVV) Analytical Services, a comprehensive suite of analytical testing solutions specifically designed for LVV and cell therapy programs.

SK pharmteco Launches New Lentiviral Vector Analytical Services with Dedicated 20,000 sq. ft. Facility 

FOR IMMEDIATE RELEASE  SK pharmteco Launches New Lentiviral Vector Analytical Services with Dedicated 20,000 sq. ft. Facility  King of Prussia, PA (May 21, 2024)—SK pharmteco, a global contract development, manufacturing, and analytical testing organization serving the pharmaceutical and cell & gene therapy industry, today announced the upcoming launch of Lentiviral Vector (LVV) Analytical Services, a […]

SK pharmteco Launches New Lentiviral Vector Analytical Services with Dedicated 20,000 sq. ft. Facility  Read More »

SK pharmteco to Showcase Breakthroughs in Drug Manufacturing at ASGCT Meeting in Baltimore

FOR IMMEDIATE RELEASE SK pharmteco to Showcase Breakthroughs in Drug Manufacturing at ASGCT Meeting in Baltimore   RANCHO CORDOVA, Ca. (May 6, 2024) – SK pharmteco, a global contract development and manufacturing organization serving the pharmaceutical industry, will unveil advancements in gene and cell therapy manufacturing through eightresearch poster presentations at the upcoming annual meeting of

SK pharmteco to Showcase Breakthroughs in Drug Manufacturing at ASGCT Meeting in Baltimore Read More »

Ferring Pharmaceuticals and SK pharmteco enter into commercial gene therapy manufacturing deal

Biopharmaceutical contract manufacturer SK pharmteco commits to production, testing, and release of Ferring’s U.S. approved Adstiladrin® (nadofaragene firadenovec-vncg) The deal assures diversity of supply to meet future long-term plans for expanded availability of the gene therapy Two additional state-of-the-art manufacturing facilities for Adstiladrin® are near completion in Finland and the U.S. Saint-Prex, Switzerland and King

Ferring Pharmaceuticals and SK pharmteco enter into commercial gene therapy manufacturing deal Read More »

John Lee, Global Head of CGT Published in Cytotherapy – CGT Development: Selecting the Right CDMO

Cell and Gene Therapy Development: Selecting the Right Contract Development and Manufacturing Organization In recent years, the number of cell and gene therapy (CGT) clinical trials has boomed, and so has the need for contract development and manufacturing organizations (CDMOs).  For any size biotech company developing CGT products,  selecting the right CDMO is crucial for

John Lee, Global Head of CGT Published in Cytotherapy – CGT Development: Selecting the Right CDMO Read More »

Julie Osborne joins SK pharmteco as VP, Global HR

We are pleased to announce that Julie Osborne has joined SK pharmteco as VP, Global HR. Julie has held several progressing roles supporting Global Marketing and sales, Controlled Substance Manufacturing, Regulatory Affairs, Quality, and R&D. As a Division Vice President for Global Pharmaceutical R&D, Julie maintained Business and HR responsibilities across six countries, including Japan,

Julie Osborne joins SK pharmteco as VP, Global HR Read More »

AI in Bio/Pharma Supply Chain: SK pharmteco Expert Shares Insights at DCAT Week

At DCAT Week, the buzz wasn’t just about the latest drug discovery techniques – it was about AI’s growing influence on bio/pharma supply chains.  SK pharmteco was at the forefront of this conversation when Jeet Sarkar, SK pharmteco’s global head of Information Technology (IT), took center stage on a panel discussing how biopharma companies utilize

AI in Bio/Pharma Supply Chain: SK pharmteco Expert Shares Insights at DCAT Week Read More »

From The Korea Economic Daily: SK pharmteco Launches New Viral Vector Platforms, Key for CGT

The Korean CDMO’s new viral vector platforms can significantly save the production time and cost of AAV and lentiviral vectors By Ji-Hyun Lee SK pharmteco Co., South Korean conglomerate SK Group’s contract development and manufacturing organization (CDMO), has recently introduced two new viral vector platforms that are expected to save the time and cost of

From The Korea Economic Daily: SK pharmteco Launches New Viral Vector Platforms, Key for CGT Read More »

SK pharmteco’s subsidiary Yposkesi launches AAVelocity, a plug-and-play Adeno-Associated Virus (AAV) platform

Designed to shorten turnaround on manufacturing AAVs, this new platform offers Cell and Gene Therapy developers more flexibility in producing viral vectors for clinical and commercial use Evry-Courcouronnes (near Paris), France, November 7, 2023 – Yposkesi, SK pharmteco’s European clinical and commercial viral vector manufacturing subsidiary for Cell and Gene Therapies (C&GT), today launches AAVelocityTM,

SK pharmteco’s subsidiary Yposkesi launches AAVelocity, a plug-and-play Adeno-Associated Virus (AAV) platform Read More »

SK pharmteco to Showcase its Extensive APIs and CGT Capabilities at CPHI 2023

RANCHO CORDOVA, Calif. and KING OF PRUSSIA, Pa., Oct. 18, 2023 /PRNewswire/ — SK pharmteco will participate at the CPHI 2023 in Barcelona and prepare a dedicated booth at the event. As a multi-modality CDMO with expertise in small molecule active pharmaceutical ingredients (APIs) and biopharmaceuticals, SK pharmteco aims to present its business competitiveness and actively pursue business opportunities. With a dedicated booth

SK pharmteco to Showcase its Extensive APIs and CGT Capabilities at CPHI 2023 Read More »

SK pharmteco Names Andrew Fenny Chief Commercial Officer

September 27, 2023 FOR IMMEDIATE RELEASE RANCHO CORDOVA, Ca. (September 27, 2023) – SK pharmteco, a global contract development and manufacturing organization serving the pharmaceutical industry, today announced Andrew (Andy) Fenny as Chief Commercial Officer. In this newly created role, Fenny will shape customer-focused strategies and be responsible for SK pharmteco’s sales and marketing initiatives and

SK pharmteco Names Andrew Fenny Chief Commercial Officer Read More »

Scroll to Top

Enter your details to access Marketing Materials